{"id":775,"date":"2025-01-22T15:58:30","date_gmt":"2025-01-22T15:58:30","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solutions&p=775"},"modified":"2025-06-06T09:00:20","modified_gmt":"2025-06-06T09:00:20","slug":"translational-models-in-hepatic-fibrosis","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/hepatic\/translational-models-in-hepatic-fibrosis\/","title":{"rendered":"Translational Models in Hepatic Fibrosis"},"content":{"rendered":"
\n \n
\n
\n
\n
\n

Strategic drug development in hepatic fibrosis<\/h2>\n \n\n <\/div>\n
\n

Navigating the drug development process successfully is essential and not without challenges and uncertainties. Employing strategies that enhance the probability of success is crucial. The FDA and EMA acknowledge that biomarker-based drug development strategies, paired with translational research, could provide a viable solution. This approach offers a biology-centric approach that reduces both time and costs while improving the overall likelihood of success.<\/p>\n

Nordic Bioscience effectively integrates innovative translational models with\u00a0Nordic ProteinFingerPrint Technology\u2122<\/a>\u00a0to translate findings efficiently. By using the same biomarkers throughout various clinical development stages, they create a seamless link between preclinical models and clinical applications. This strategically chosen development pathway significantly boosts the efficiency of drug development pipelines.<\/p>\n

Incorporating biomarker-based drug development strategies into translational research not only speeds up therapeutic advancements but also increases the chances of success. Nordic Bioscience\u2019s advanced translational models, combined with\u00a0ProteinFingerPrint\u2122 biomarkers<\/a>, play a crucial role in optimizing clinical development decision-making processes, ultimately ensuring better treatments for patients.<\/p>\n <\/div>\n

\n

Publications<\/h3>\n